GMAB Genmab

  1. Stocks
  2. Healthcare
  3. NASDAQ: GMAB

Price (delayed)

$34.75

Market cap

$21.67B

P/E Ratio

27.15

Dividend/share

N/A

EPS

$1.28

Enterprise value

$25.44B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 32
Relative Profitability: Rel. Profitability: 81

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For ...

Highlights
Genmab's revenue has increased by 22% YoY and by 6% QoQ
The company's gross profit rose by 20% YoY and by 6% QoQ
The quick ratio has dropped by 61% year-on-year but it is up by 13% since the previous quarter
GMAB's price to earnings (P/E) is 48% higher than its last 4 quarters average of 18.6 but 13% lower than its 5-year quarterly average of 31.5
The net income has contracted by 38% YoY and by 4% from the previous quarter
The EPS has contracted by 36% YoY and by 3.8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.genmab.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of GMAB

GMAB stock price

How has the Genmab stock price performed over time
Intraday
-1.33%
1 week
1.02%
1 month
3.89%
1 year
20.95%
YTD
12.82%
QTD
26.5%

Financial performance

How have Genmab's revenue and profit performed over time
Revenue
$4.13B
Gross profit
$3.84B
Operating income
$1.07B
Net income
$788M
Gross margin
93%
Net margin
19.1%
Genmab's net margin has decreased by 49% YoY and by 9% from the previous quarter
The net income has contracted by 38% YoY and by 4% from the previous quarter
The operating margin is down by 25% YoY and by 4.1% QoQ
Genmab's revenue has increased by 22% YoY and by 6% QoQ

Price vs fundamentals

How does GMAB's price correlate with its fundamentals

Growth

What is Genmab's growth rate over time

Valuation

What is Genmab stock price valuation
GMAB P/E details
P/E
27.15
P/B
3.75
P/S
5.4
EV/EBIT
19.11
EV/EBITDA
17.85
EV/Sales
6.16
GMAB's price to earnings (P/E) is 48% higher than its last 4 quarters average of 18.6 but 13% lower than its 5-year quarterly average of 31.5
The EPS has contracted by 36% YoY and by 3.8% from the previous quarter
The P/B is 24% below the 5-year quarterly average of 5.0 but 19% above the last 4 quarters average of 3.2
The equity has grown by 12% YoY and by 4.8% from the previous quarter
The P/S is 45% below the 5-year quarterly average of 10.0 but 12% above the last 4 quarters average of 4.9
Genmab's revenue has increased by 22% YoY and by 6% QoQ

Efficiency

How efficient is Genmab business performance
The ROA has plunged by 66% YoY and by 18% from the previous quarter
Genmab's return on invested capital has shrunk by 65% YoY and by 22% QoQ
Genmab's ROE has decreased by 46% YoY and by 6% from the previous quarter
The ROS has contracted by 39% YoY and by 11% from the previous quarter

Dividends

What is GMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GMAB.

Financial health

How did Genmab financials performed over time
The total assets is 91% greater than the total liabilities
The total assets has surged by 94% year-on-year
The quick ratio has dropped by 61% year-on-year but it is up by 13% since the previous quarter
Genmab's debt is 11% less than its equity
The equity has grown by 12% YoY and by 4.8% from the previous quarter
GMAB's debt to equity is down by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.